{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:52:01Z","timestamp":1785840721202,"version":"3.56.0"},"reference-count":236,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in the\npaediatric age. The growing prevalence of NAFLD and its advanced phenotype, non-alcoholic steatohepatitis\n(NASH), in children and adolescents parallels similar trends in obesity and type 2 diabetes\nmellitus. This trend may have serious long-term implications, including hepatic and extra-hepatic morbidity\nand mortality, the latter being related mostly due to cardiovascular disease and malignancies. This\nnarrative review, which included 236 articles, summarizes current evidence on paediatric NAFLD, including\npathophysiology, risk factors, complications, prevention and treatment (existing and emerging).\nEarly recognition of NAFLD followed by timely and adequate management seems to be important on an\nindividual basis. A global \u201ccall to action\u201d regarding paediatric NAFLD seems appropriate to mitigate\nthe burden of this disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570161121666221118155136","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T05:37:19Z","timestamp":1669095439000},"page":"4-25","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Non-alcoholic Fatty Liver Disease in Children"],"prefix":"10.2174","volume":"21","author":[{"given":"Emir","family":"Muzurovi\u0107","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Endocrinology Section, Clinical Centre of Montenegro, Podgorica, Montenegro"},{"name":"Faculty of Medicine, University of Montenegro, Ljubljanska bb, 81000, Podgorica, Montenegro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[{"name":"First Laboratory of\nPharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri P.","family":"Mikhailidis","sequence":"additional","affiliation":[{"name":"Department of Clinical\nBiochemistry, Royal Free Hospital Campus, Medical School, University College London (UCL), Pond Street, London\nNW3 2QG, UK"},{"name":"Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Borozan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Endocrinology Section, Clinical Centre of Montenegro, Podgorica, Montenegro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du\u0161anka","family":"Novosel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Montenegro, Ljubljanska bb, 81000, Podgorica, Montenegro"},{"name":"Institute for Children's\nDiseases, Gastroenterology Section, Clinical Centre of Montenegro, Podgorica, Montenegro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Cmiljani\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Montenegro, Ljubljanska bb, 81000, Podgorica, Montenegro"},{"name":"Institute for Children's\nDiseases, Gastroenterology Section, Clinical Centre of Montenegro, Podgorica, Montenegro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u0161a","family":"Kadi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Montenegro, Ljubljanska bb, 81000, Podgorica, Montenegro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[{"name":"Departments of\nMedicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA and Boston VA\nHealthcare System, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1053\/j.gastro.2016.03.009","volume":"150","author":"Nobili V.","year":"2016","unstructured":"Nobili V.; Alisi A.; Newton K.P.; Schwimmer J.B.; Comparison of the phenotype and approach to pediatric vs. adult patients with nonalcoholic fatty liver disease. Gastroenterology 2016,150(8),1798-1810","journal-title":"Gastroenterology"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","volume":"65","author":"Fazel Y.","year":"2016","unstructured":"Fazel Y.; Koenig A.B.; Sayiner M.; Goodman Z.D.; Younossi Z.M.; Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 2016,65(8),1017-1025","journal-title":"Metabolism"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","volume":"64","author":"Vos M.B.","year":"2017","unstructured":"Vos M.B.; Abrams S.H.; Barlow S.E.; NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in Children: Recommendations from the expert committee on NAFLD (ECON) and the North American society of pediatric gastroenterology, hepatology and nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017,64(2),319-334","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/000992280404300512","volume":"43","author":"Fishbein M.","year":"2004","unstructured":"Fishbein M.; Cox S.; Non-alcoholic fatty liver disease in a toddler. Clin Pediatr (Phila) 2004,43(5),483-485","journal-title":"Clin Pediatr (Phila)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.14341\/2071-8713-5285","volume":"7","author":"Feldstein A.E.","year":"2010","unstructured":"Feldstein A.E.; Charatcharoenwitthaya P.; Treeprasertsuk S.; Benson J.T.; Enders F.B.; Angulo P.; The natural history of non-alcoholic fatty liver disease in children: A follow-up study for up to 20 years. Obes Metab 2010,7(1),69-70","journal-title":"Obes Metab"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/nrgastro.2011.273","volume":"9","author":"Alisi A.","year":"2012","unstructured":"Alisi A.; Feldstein A.E.; Villani A.; Raponi M.; Nobili V.; Pediatric nonalcoholic fatty liver disease: A multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012,9(3),152-161","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41575-019-0169-z","volume":"16","author":"Nobili V.","year":"2019","unstructured":"Nobili V.; Alisi A.; Valenti L.; Miele L.; Feldstein A.E.; Alkhouri N.; NAFLD in children: New genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol 2019,16(9),517-530","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jhep.2019.06.023","volume":"71","author":"Nobili V.","year":"2019","unstructured":"Nobili V.; Mantovani A.; Cianfarani S.; Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. J Hepatol 2019,71(4),802-810","journal-title":"J Hepatol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.pcl.2017.01.008","volume":"64","author":"Selvakumar P.K.C.","year":"2017","unstructured":"Selvakumar P.K.C.; Kabbany M.N.; Nobili V.; Alkhouri N.; Nonalcoholic fatty liver disease in children. Pediatr Clin North Am 2017,64(3),659-675","journal-title":"Pediatr Clin North Am"},{"key":"ref=10","first-page":"92","volume":"42","author":"Polyzos S.A.","year":"2017","unstructured":"Polyzos S.A.; Kountouras J.; Mantzoros C.S.; Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol 2017,42(2),92-108","journal-title":"Minerva Endocrinol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cld.2017.08.002","volume":"22","author":"Goyal N.P.","year":"2018","unstructured":"Goyal N.P.; Schwimmer J.B.; The genetics of pediatric nonalcoholic fatty liver disease. Clin Liver Dis 2018,22(1),59-71","journal-title":"Clin Liver Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"154822","DOI":"10.1016\/j.metabol.2021.154822","volume":"122","author":"Kanwal F.","year":"2021","unstructured":"Kanwal F.; Shubrook J.H.; Younossi Z.; Preparing for the NASH epidemic: A call to action. Metabolism 2021,122,154822","journal-title":"Metabolism"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.metabol.2013.10.010","volume":"63","author":"Polyzos S.A.","year":"2014","unstructured":"Polyzos S.A.; Mantzoros C.S.; Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 2014,63(2),161-167","journal-title":"Metabolism"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jhep.2012.07.027","volume":"57","author":"Alkhouri N.","year":"2012","unstructured":"Alkhouri N.; De Vito R.; Alisi A.; Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. J Hepatol 2012,57(6),1312-1318","journal-title":"J Hepatol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1542\/peds.2006-1212","volume":"118","author":"Schwimmer J.B.","year":"2006","unstructured":"Schwimmer J.B.; Deutsch R.; Kahen T.; Lavine J.E.; Stanley C.; Behling C.; Prevalence of fatty liver in children and adolescents. Pediatrics 2006,118(4),1388-1393","journal-title":"Pediatrics"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.pcl.2011.09.005","volume":"58","author":"Mencin A.A.","year":"2011","unstructured":"Mencin A.A.; Lavine J.E.; Advances in pediatric nonalcoholic fatty liver disease. Pediatr Clin North Am x.2011,58(6),1375-1392","journal-title":"Pediatr Clin North Am"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.cgh.2008.11.005","volume":"7","author":"Rafiq N.","year":"2009","unstructured":"Rafiq N.; Bai C.; Fang Y.; Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009,7(2),234-238","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1007\/s10620-014-3494-7","volume":"60","author":"Mansoor S.","year":"2015","unstructured":"Mansoor S.; Yerian L.; Kohli R.; The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Dig Dis Sci 2015,60(5),1440-1447","journal-title":"Dig Dis Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/MPG.0b013e3181fb47d3","volume":"52","author":"Carter-Kent C.","year":"2011","unstructured":"Carter-Kent C.; Brunt E.M.; Yerian L.M.; Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2011,52(2),190-197","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cld.2015.10.003","volume":"20","author":"Goyal N.P.","year":"2016","unstructured":"Goyal N.P.; Schwimmer J.B.; The progression and natural history of pediatric nonalcoholic fatty liver disease. Clin Liver Dis 2016,20(2),325-338","journal-title":"Clin Liver Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/liv.12024","volume":"33","author":"Alkhouri N.","year":"2013","unstructured":"Alkhouri N.; Sedki E.; Alisi A.; Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int 2013,33(1),79-85","journal-title":"Liver Int"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.cgh.2008.03.001","volume":"6","author":"Akader H.","year":"2008","unstructured":"Akader H.; Henderson J.; Vanhoesen K.; Ghishan F.; Bhattacharyya A.; Nonalcoholic fatty liver disease in children: A single center experience. Clin Gastroenterol Hepatol 2008,6(7),799-802","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1136\/gut.2008.171280","volume":"58","author":"Feldstein A.E.","year":"2009","unstructured":"Feldstein A.E.; Charatcharoenwitthaya P.; Treeprasertsuk S.; Benson J.T.; Enders F.B.; Angulo P.; The natural history of non-alcoholic fatty liver disease in children: A follow-up study for up to 20 years. Gut 2009,58(11),1538-1544","journal-title":"Gut"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/14656566.2019.1702967","volume":"21","author":"Doulberis M.","year":"2020","unstructured":"Doulberis M.; Polyzos S.A.; Papaefthymiou A.; Katsinelos P.; Kiosses C.; Kountouras J.; Treatment of nonalcoholic fatty liver disease: From adult trials to perspectives in the management of children and adolescents. Expert Opin Pharmacother 2020,21(3),247-251","journal-title":"Expert Opin Pharmacother"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/MCG.0b013e31824587e0","volume":"46","author":"Polyzos S.A.","year":"2012","unstructured":"Polyzos S.A.; Kountouras J.; Zavos C.; Deretzi G.; Nonalcoholic fatty liver disease: Multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 2012,46(4),272-284","journal-title":"J Clin Gastroenterol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"e1920294","DOI":"10.1001\/jamanetworkopen.2019.20294","volume":"3","author":"Wong R.J.","year":"2020","unstructured":"Wong R.J.; Singal A.K.; Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019. JAMA Netw Open 2020,3(2),e1920294","journal-title":"JAMA Netw Open"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/tri.12694","volume":"29","author":"Alkhouri N.","year":"2016","unstructured":"Alkhouri N.; Hanouneh I.A.; Zein N.N.; Liver transplantation for nonalcoholic steatohepatitis in young patients. Transpl Int 2016,29(4),418-424","journal-title":"Transpl Int"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1111\/j.2047-6310.2013.00209.x","volume":"9","author":"Nobili V.","year":"2014","unstructured":"Nobili V.; Alisi A.; Grimaldi C.; Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: Coincidence or comorbidity? Pediatr Obes 2014,9(5),e99-e102","journal-title":"Pediatr Obes"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1038\/ajg.2010.152","volume":"105","author":"Patton H.M.","year":"2010","unstructured":"Patton H.M.; Yates K.; Unalp-Arida A.; Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease. Am J Gastroenterol 2010,105(9),2093-2102","journal-title":"Am J Gastroenterol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.ijo.0803711","volume":"32","author":"Manco M.","year":"2008","unstructured":"Manco M.; Marcellini M.; DeVito R.; Comparcola D.; Sartorelli M.R.; Nobili V.; Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes 2008,32(2),381-387","journal-title":"Int J Obes"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1067\/S0022-3476(03)00325-1","volume":"143","author":"Schwimmer J.B.","year":"2003","unstructured":"Schwimmer J.B.; Deutsch R.; Rauch J.B.; Behling C.; Newbury R.; Lavine J.E.; Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003,143(4),500-505","journal-title":"J Pediatr"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1210\/jcem.83.9.5143","volume":"83","author":"Tritos N.A.","year":"1998","unstructured":"Tritos N.A.; Mantzoros C.S.; Clinical review 97: Syndromes of severe insulin resistance. J Clin Endocrinol Metab 1998,83(9),3025-3030","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1161\/CIRCULATIONAHA.107.739920","volume":"118","author":"Schwimmer J.B.","year":"2008","unstructured":"Schwimmer J.B.; Pardee P.E.; Lavine J.E.; Blumkin A.K.; Cook S.; Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008,118(3),277-283","journal-title":"Circulation"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.2174\/1570161114666160722112738","volume":"14","author":"Katsiki N.","year":"2016","unstructured":"Katsiki N.; Athyros V.G.; Mikhailidis D.P.; Abnormal peri-organ or intra-organ fat (apifat) deposition: An underestimated predictor of vascular risk? Curr Vasc Pharmacol 2016,14(5),432-441","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/10742484211006997","volume":"26","year":"2021","unstructured":"Muzurovi\u0107 EM, Vujo\u0161evi\u0107 S, Mikhailidis DP. Can we decrease epicardial and pericardial fat in patients with diabetes? J Cardiovasc Pharmacol Ther 2021,26(5),415-436","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2174\/157016112001211228145754","volume":"20","year":"2022","unstructured":"Muzurovi\u0107 E, Coji\u0107 M, Stankovi\u0107 Z, Jane\u017e A. Epicardial adipocyte-derived TNF-\u03b1 modulates local inflammation in patients with advanced coronary artery disease. Curr Vasc Pharmacol 2022,20(1),94-95","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/jcu.22602","volume":"46","author":"Akkurt M.O.","year":"2018","unstructured":"Akkurt M.O.; Turan O.M.; Crimmins S.; Harman C.R.; Turan S.; Increased fetal epicardial fat thickness: A novel ultrasound marker for altered fetal metabolism in diabetic pregnancies. J Clin Ultrasound 2018,46(6),397-402","journal-title":"J Clin Ultrasound"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.cjca.2012.07.846","volume":"29","author":"Alp H.","year":"2013","unstructured":"Alp H.; Karaarslan S.; Selver Eklio\u011flu B, Atabek ME, Alt\u0131n H, Baysal T. Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents. Can J Cardiol 2013,29(9),1118-1125","journal-title":"Can J Cardiol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e161971","DOI":"10.1001\/jamapediatrics.2016.1971","volume":"170","author":"Newton K.P.","year":"2016","unstructured":"Newton K.P.; Hou J.; Crimmins N.A.; Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr 2016,170(10),e161971","journal-title":"JAMA Pediatr"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1053\/j.gastro.2016.12.051","volume":"152","author":"Caprio S.","year":"2017","unstructured":"Caprio S.; Perry R.; Kursawe R.; Adolescent obesity and insulin resistance: Roles of ectopic fat accumulation and adipose inflammation. Gastroenterology 2017,152(7),1638-1646","journal-title":"Gastroenterology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/children4050034","volume":"4","author":"Cioffi C.E.","year":"2017","unstructured":"Cioffi C.E.; Welsh J.A.; Cleeton R.L.; Natural history of NAFLD diagnosed in childhood: A single-center study. Children (Basel) 2017,4(5),34","journal-title":"Children (Basel)"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1464-5491.2010.03093.x","volume":"27","author":"Wlazlo N.","year":"2010","unstructured":"Wlazlo N.; Beijers H.J.B.H.; Schoon E.J.; Sauerwein H.P.; Stehouwer C.D.A.; Bravenboer B.; High prevalence of diabetes mellitus in patients with liver cirrhosis. Diabet Med 2010,27(11),1308-1311","journal-title":"Diabet Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1203\/PDR.0b013e3181da4798","volume":"67","author":"Nobili V.","year":"2010","unstructured":"Nobili V.; Alkhouri N.; Bartuli A.; Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr Res 2010,67(6),665-670","journal-title":"Pediatr Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/MPG.0000000000000584","volume":"60","author":"Corey K.E.","year":"2015","unstructured":"Corey K.E.; Vuppalanchi R.; Vos M.; Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2015,60(3),360-367","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"e112569","DOI":"10.1371\/journal.pone.0112569","volume":"9","author":"Schwimmer J.B.","year":"2014","unstructured":"Schwimmer J.B.; Zepeda A.; Newton K.P.; Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease. PLoS One 2014,9(11),e112569","journal-title":"PLoS One"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"154770","DOI":"10.1016\/j.metabol.2021.154770","volume":"119","year":"2021","unstructured":"Muzurovi\u0107 E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 2021,119,154770","journal-title":"Metabolism"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4254\/wjh.v9.i2.69","volume":"9","author":"Di Sessa A.","year":"2017","unstructured":"Di Sessa A.; Umano G.R.; Miraglia del Giudice E.; Santoro N.; From the liver to the heart: Cardiac dysfunction in obese children with non-alcoholic fatty liver disease. World J Hepatol 2017,9(2),69-73","journal-title":"World J Hepatol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/MPG.0b013e3181d4c21d","volume":"51","author":"Caserta C.A.","year":"2010","unstructured":"Caserta C.A.; Pendino G.M.; Alicante S.; Body mass index, cardiovascular risk factors, and carotid intima-media thickness in a pediatric population in southern Italy. J Pediatr Gastroenterol Nutr 2010,51(2),216-220","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/MPG.0b013e31816232c9","volume":"47","year":"2008","unstructured":"Demircio\u011flu F, Ko\u00e7yi\u011fit A, Arslan N, \u00c7akmak\u00e7 H, Hzl \u015e Sedat AT. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2008,47(1),68-75","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1203\/PDR.0b013e318165b8e7","volume":"63","author":"Pacifico L.","year":"2008","unstructured":"Pacifico L.; Cantisani V.; Ricci P.; Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res 2008,63(4),423-427","journal-title":"Pediatr Res"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","volume":"71","author":"Simon T.G.","year":"2022","unstructured":"Simon T.G.; Roelstraete B.; Hagstr\u00f6m H.; Sundstr\u00f6m J.; Ludvigsson J.F.; Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut 2022,71(9),1867-1875","journal-title":"Gut"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jceh.2021.08.016","volume":"12","author":"Kaur H.","year":"2022","unstructured":"Kaur H.; Premkumar M.; Diagnosis and management of cirrhotic cardiomyopathy. J Clin Exp Hepatol 2022,12(1),186-199","journal-title":"J Clin Exp Hepatol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1161\/HYPERTENSIONAHA.122.17982","volume":"79","year":"2022","unstructured":"Muzurovi\u0107 E, Peng CCH, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic fatty liver disease and cardiovascular disease: A review of shared cardiometabolic risk factors. Hypertension 2022,79(7),1319-1326","journal-title":"Hypertension"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s12072-015-9689-y","volume":"10","author":"Eslam M.","year":"2016","unstructured":"Eslam M.; George J.; Genetic and epigenetic mechanisms of NASH. Hepatol Int 2016,10(3),394-406","journal-title":"Hepatol Int"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"e855","DOI":"10.1016\/j.cgh.2020.12.033","volume":"20","author":"Liu Z.","year":"2022","unstructured":"Liu Z.; Suo C.; Shi O.; The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease\u2013related genetic variants. Clin Gastroenterol Hepatol 2022,20(4),e855-e875","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"Buzzetti E.","year":"2016","unstructured":"Buzzetti E.; Pinzani M.; Tsochatzis E.A.; The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016,65(8),1038-1048","journal-title":"Metabolism"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1053\/j.gastro.2020.01.048","volume":"158","author":"Goldner D.","year":"2020","unstructured":"Goldner D.; Lavine J.E.; Nonalcoholic fatty liver disease in children: Unique considerations and challenges. Gastroenterology 2020,158(7),1967-1983.e1","journal-title":"Gastroenterology"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1111\/j.1572-0241.2001.04667.x","volume":"96","author":"Willner I.R.","year":"2001","unstructured":"Willner I.R.; Waters B.; Patil S.R.; Reuben A.; Morelli J.; Riely C.A.; Ninety patients with nonalcoholic steatohepatitis: Insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001,96(10),2957-2961","journal-title":"Am J Gastroenterol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/hep.20466","volume":"40","author":"Browning J.D.","year":"2004","unstructured":"Browning J.D.; Szczepaniak L.S.; Dobbins R.; Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004,40(6),1387-1395","journal-title":"Hepatology"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jhep.2008.12.025","volume":"50","author":"Makkonen J.","year":"2009","unstructured":"Makkonen J.; Pietil\u00e4inen K.H.; Rissanen A.; Kaprio J.; Yki-J\u00e4rvinen H.; Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: A study in monozygotic and dizygotic twins. J Hepatol 2009,50(5),1035-1042","journal-title":"J Hepatol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1053\/j.gastro.2010.06.009","volume":"139","author":"Loomba R","year":"2010","unstructured":"Loomba R; Rao F; Zhang L; Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology 2010,139(3),836-845.e1, 845.e1.","journal-title":"Gastroenterology"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1055\/s-0039-1679920","volume":"39","author":"Sookoian S.","year":"2019","unstructured":"Sookoian S.; Pirola C.; Genetics of nonalcoholic fatty liver disease: From pathogenesis to therapeutics. Semin Liver Dis 2019,39(2),124-140","journal-title":"Semin Liver Dis"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/apt.14210","volume":"46","author":"Townsend S.A.","year":"2017","unstructured":"Townsend S.A.; Newsome P.N.; New treatments in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017,46(5),494-507","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.metabol.2016.08.001","volume":"66","author":"Polyzos S.A.","year":"2017","unstructured":"Polyzos S.A.; Bugianesi E.; Kountouras J.; Mantzoros C.S.; Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-\u03b3 agonists. Metabolism 2017,66,64-68","journal-title":"Metabolism"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/j.cgh.2020.08.054","volume":"19","author":"Lazo M.","year":"2021","unstructured":"Lazo M.; Bilal U.; Mitchell M.C.; Potter J.; Hernaez R.; Clark J.M.; Interaction between alcohol consumption and pnpla3 variant in the prevalence of hepatic steatosis in the US population. Clin Gastroenterol Hepatol 2021,19(12),2606-2614.e4","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2010.02.034","volume":"53","author":"Romeo S.","year":"2010","unstructured":"Romeo S.; Sentinelli F.; Cambuli V.M.; The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 2010,53(2),335-338","journal-title":"J Hepatol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"Romeo S.","year":"2008","unstructured":"Romeo S.; Kozlitina J.; Xing C.; Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008,40(12),1461-1465","journal-title":"Nat Genet"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"37085","DOI":"10.1074\/jbc.M111.290114","volume":"286","author":"Huang Y.","year":"2011","unstructured":"Huang Y.; Cohen J.C.; Hobbs H.H.; Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem 2011,286(43),37085-37093","journal-title":"J Biol Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"6706","DOI":"10.1074\/jbc.M109.064501","volume":"285","author":"He S.","year":"2010","unstructured":"He S.; McPhaul C.; Li J.Z.; A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010,285(9),6706-6715","journal-title":"J Biol Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.bbrc.2014.03.078","volume":"446","author":"Winberg M.E.","year":"2014","unstructured":"Winberg M.E.; Khalaj Motlagh M.; Stenkula K.G.; Holm C.; Jones H.A.; Adiponutrin: A multimeric plasma protein. Biochem Biophys Res Commun 2014,446(4),1114-1119","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3109\/00365521.2016.1161066","volume":"51","author":"Vespasiani-Gentilucci U.","year":"2016","unstructured":"Vespasiani-Gentilucci U.; Gallo P.; Porcari A.; The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scand J Gastroenterol 2016,51(8),967-973","journal-title":"Scand J Gastroenterol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","volume":"61","author":"Liu Y.L.","year":"2014","unstructured":"Liu Y.L.; Patman G.L.; Leathart J.B.S.; Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014,61(1),75-81","journal-title":"J Hepatol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/cncr.31122","volume":"124","author":"Tepper C.G.","year":"2018","unstructured":"Tepper C.G.; Dang J.H.T.; Stewart S.L.; High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer 2018,124(Suppl. 7),1583-1589","journal-title":"Cancer"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/hep.23832","volume":"52","author":"Santoro N.","year":"2010","unstructured":"Santoro N.; Kursawe R.; D\u2019Adamo E.; A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010,52(4),1281-1290","journal-title":"Hepatology"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"Kozlitina J.","year":"2014","unstructured":"Kozlitina J.; Smagris E.; Stender S.; Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014,46(4),352-356","journal-title":"Nat Genet"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/TP.0000000000002876","volume":"104","author":"M\u00edkov\u00e1 I","year":"2020","unstructured":"M\u00edkov\u00e1 I; , Ne\u0159oldov\u00e1 M, Hub\u00e1\u010dek JA, et al. Donor PNPLA3 and TM6SF2 variant alleles confer additive risks for graft steatosis after liver transplantation. Transplantation 2020,104(3),526-534","journal-title":"Transplantation"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/hep.28283","volume":"63","author":"Goffredo M.","year":"2016","unstructured":"Goffredo M.; Caprio S.; Feldstein A.E.; Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study. Hepatology 2016,63(1),117-125","journal-title":"Hepatology"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/ijpo.12032","volume":"11","author":"Grandone A.","year":"2016","unstructured":"Grandone A.; Cozzolino D.; Marzuillo P.; TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children. Pediatr Obes 2016,11(2),115-119","journal-title":"Pediatr Obes"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/pr.2016.3","volume":"79","author":"Viitasalo A.","year":"2016","unstructured":"Viitasalo A.; Pihlajam\u00e4ki J.; Paananen J.; Atalay M.; Lindi V.; Lakka T.A.; Associations of TM6SF2 167K allele with liver enzymes and lipid profile in children: the PANIC Study. Pediatr Res 2016,79(5),684-688","journal-title":"Pediatr Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/00365513.2019.1700428","volume":"80","author":"K\u00e4r\u00e4j\u00e4m\u00e4ki A.J.","year":"2020","unstructured":"K\u00e4r\u00e4j\u00e4m\u00e4ki A.J.; Hukkanen J.; Kauma H.; Kes\u00e4niemi Y.A.; Ukkola O.; Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study). Scand J Clin Lab Invest 2020,80(2),106-113","journal-title":"Scand J Clin Lab Invest"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/apt.16575","volume":"54","author":"Polyzos S.A.","year":"2021","unstructured":"Polyzos S.A.; Kechagias S.; Tsochatzis E.A.; Review article: non\u2010alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021,54(8),1013-1025","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"e12852","DOI":"10.1111\/ijpo.12852","volume":"17","author":"Lee K.J.","year":"2022","unstructured":"Lee K.J.; Moon J.S.; Kim N.Y.; Ko J.S.; Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non\u2010alcoholic fatty liver disease in children. Pediatr Obes 2022,17(2),e12852","journal-title":"Pediatr Obes"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3389\/fgene.2016.00140","volume":"7","author":"Wang X.","year":"2016","unstructured":"Wang X.; Liu Z.; Wang K.; Additive effects of the risk alleles of PNPLA3 and TM6SF2 on non-alcoholic fatty liver disease (NAFLD) in a Chinese population. Front Genet 2016,7,140","journal-title":"Front Genet"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1038\/ncomms5309","volume":"5","author":"Liu Y.L.","year":"2014","unstructured":"Liu Y.L.; Reeves H.L.; Burt A.D.; TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014,5(1),4309","journal-title":"Nat Commun"},{"key":"ref=85","first-page":"156","volume":"29","author":"Bing H.","year":"2021","unstructured":"Bing H.; Wang W.; Li Y.L.; Correlation between PNPLA3 rs738409 and TM6SF2 rs58542926 gene polymorphism and primary liver cancer in the Han population of China\u2019s Northeast region. Clin J Hepatol 2021,29(2),156-162","journal-title":"Clin J Hepatol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1016\/j.cgh.2020.02.011","volume":"18","author":"Koo B.K.","year":"2020","unstructured":"Koo B.K.; Joo S.K.; Kim D.; Development and validation of a scoring system, based on genetic and clinical factors, to determine risk of steatohepatitis in Asian patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2020,18(11),2592-2599.e10","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jhep.2016.07.045","volume":"65","author":"Luukkonen P.K.","year":"2016","unstructured":"Luukkonen P.K.; Zhou Y.; Hy\u00f6tyl\u00e4inen T.; The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. J Hepatol 2016,65(6),1263-1265","journal-title":"J Hepatol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","volume":"150","author":"Mancina R.M.","year":"2016","unstructured":"Mancina R.M.; Dongiovanni P.; Petta S.; The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 2016,150(5),1219-1230.e6","journal-title":"Gastroenterology"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/MPG.0000000000001979","volume":"67","author":"Di Sessa A.","year":"2018","unstructured":"Di Sessa A.; Umano G.R.; Cirillo G.; The membrane-bound o-acyltransferase7 rs641738 variant in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2018,67(1),69-74","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/ajg.2018.1","volume":"113","author":"Umano G.R.","year":"2018","unstructured":"Umano G.R.; Caprio S.; Di Sessa A.; The rs626283 variant in the MBOAT7 gene is associated with insulin resistance and fatty liver in caucasian obese youth. Am J Gastroenterol 2018,113(3),376-383","journal-title":"Am J Gastroenterol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.numecd.2021.01.020","volume":"31","author":"Zusi C.","year":"2021","unstructured":"Zusi C.; Morandi A.; Maguolo A.; Association between MBOAT7 rs641738 polymorphism and non-alcoholic fatty liver in overweight or obese children. Nutr Metab Cardiovasc Dis 2021,31(5),1548-1555","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/hep.24806","volume":"55","author":"Santoro N.","year":"2012","unstructured":"Santoro N.; Zhang C.K.; Zhao H.; Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2012,55(3),781-789","journal-title":"Hepatology"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"e87523","DOI":"10.1371\/journal.pone.0087523","volume":"9","author":"Petta S.","year":"2014","unstructured":"Petta S.; Miele L.; Bugianesi E.; Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS One 2014,9(2),e87523","journal-title":"PLoS One"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/jgh.12714","volume":"30","author":"Zain S.M.","year":"2015","unstructured":"Zain S.M.; Mohamed Z.; Mohamed R.; A common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: A meta-analysis. J Gastroenterol Hepatol 2015,30(1),21-27","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","volume":"378","author":"Abul-Husn N.S.","year":"2018","unstructured":"Abul-Husn N.S.; Cheng X.; Li A.H.; A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med 2018,378(12),1096-1106","journal-title":"N Engl J Med"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.cmet.2012.04.008","volume":"15","author":"Kumari M.","year":"2012","unstructured":"Kumari M.; Schoiswohl G.; Chitraju C.; Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab 2012,15(5),691-702","journal-title":"Cell Metab"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"7564835","DOI":"10.1155\/2018\/7564835","volume":"2018","author":"Vespasiani-Gentilucci U.","year":"2018","unstructured":"Vespasiani-Gentilucci U.; Dell\u2019Unto C.; De Vincentis A.; Combining genetic variants to improve risk prediction for NAFLD and its progression to cirrhosis: A proof of concept study. Can J Gastroenterol Hepatol 2018,2018,7564835","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/MPG.0b013e3182442a55","volume":"54","author":"Valenti L.","year":"2012","unstructured":"Valenti L.; Motta B.M.; Alisi A.; LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2012,54(5),588-593","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2174\/1570161118666201015152921","volume":"19","author":"Sfikas G.","year":"2021","unstructured":"Sfikas G.; Psallas M.; Koumaras C.; Prevalence, diagnosis, and treatment with 3 different statins of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis in military personnel. Do genetics play a role? Curr Vasc Pharmacol 2021,19(5),572-581","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"582","DOI":"10.2174\/1570161118666201008162537","volume":"19","year":"2021","unstructured":"Muzurovi\u0107 E, Smolovi\u0107 B, Vujo\u0161evi\u0107 S, Petakov M. Editorial on prevalence, diagnosis and treatment with 3 different statins of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis in military personnel. Do genetics play a role? Curr Vasc Pharmacol 2021,19(5),582-584","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"2746909","DOI":"10.1155\/2016\/2746909","volume":"2016","author":"Valenzuela F.J.","year":"2016","unstructured":"Valenzuela F.J.; Vera J.; Venegas C.; Evidences of polymorphism associated with circadian system and risk of pathologies: A review of the literature. Int J Endocrinol 2016,2016,2746909","journal-title":"Int J Endocrinol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"12","DOI":"10.35841\/genetics-molecular-biology.1.1.12-13","volume":"1","author":"G\u00f3mez R.","year":"2017","unstructured":"G\u00f3mez R.; The role of population genetics and its implications in the study of complex-Disease risk. J Genet Mol Biol 2017,1(1),12-13","journal-title":"J Genet Mol Biol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"086","DOI":"10.1055\/s-0038-1677517","volume":"39","author":"Younes R","year":"2019","unstructured":"Younes R; Bugianesi E.; NASH in lean individuals. Semin Liver Dis 2019,39(1),086-95","journal-title":"Semin Liver Dis"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s12072-013-9477-5","volume":"7","author":"Das K.","year":"2013","unstructured":"Das K.; Chowdhury A.; Lean NASH: distinctiveness and clinical implication. Hepatol Int 2013,7(Suppl. 2),806-813","journal-title":"Hepatol Int"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2014.08.041","volume":"62","author":"Wong V.W.S.","year":"2015","unstructured":"Wong V.W.S.; Wong G.L.H.; Yeung D.K.W.; Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy. J Hepatol 2015,62(1),182-189","journal-title":"J Hepatol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/MPG.0000000000000279","volume":"58","author":"Nobili V.","year":"2014","unstructured":"Nobili V.; Donati B.; Panera N.; A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2014,58(5),632-636","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"e17641","DOI":"10.5812\/hepatmon.17641","volume":"14","author":"Manti S.","year":"2014","unstructured":"Manti S.; Romano C.; Chirico V.; Nonalcoholic fatty liver disease\/non-alcoholic steatohepatitis in childhood: endocrine-metabolic \u201cmal-programming\u201d. Hepat Mon 2014,14(4),e17641","journal-title":"Hepat Mon"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2431-13-40","volume":"13","author":"Giorgio V.","year":"2013","unstructured":"Giorgio V.; Prono F.; Graziano F.; Nobili V.; Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr 2013,13(1),40","journal-title":"BMC Pediatr"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0038-1627456","volume":"38","author":"Mann J.","year":"2018","unstructured":"Mann J.; Valenti L.; Scorletti E.; Byrne C.; Nobili V.; Nonalcoholic fatty liver disease in children. Semin Liver Dis 2018,38,1-13","journal-title":"Semin Liver Dis"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jpeds.2012.11.017","volume":"162","author":"Brumbaugh D.E.","year":"2013","unstructured":"Brumbaugh D.E.; Tearse P.; Cree-Green M.; Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes. J Pediatr 2013,162(5),930-936.e1","journal-title":"J Pediatr"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1203\/PDR.0b013e318225f9b1","volume":"70","author":"Modi N.","year":"2011","unstructured":"Modi N.; Murgasova D.; Ruager-Martin R.; The influence of maternal body mass index on infant adiposity and hepatic lipid content. Pediatr Res 2011,70(3),287-291","journal-title":"Pediatr Res"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.26389","volume":"58","author":"Vos M.B.","year":"2013","unstructured":"Vos M.B.; Furthering the understanding of maternal obesity in nonalcoholic fatty liver disease. Hepatology 2013,58(1),4-5","journal-title":"Hepatology"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.2337\/dc19-0571","volume":"42","author":"Knorr S.","year":"2019","unstructured":"Knorr S.; Bytoft B.; Lohse Z.; Fatty liver among adolescent offspring of women with type 1 diabetes (the EPICOM Study). Diabetes Care 2019,42(8),1560-1568","journal-title":"Diabetes Care"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"437107","DOI":"10.1155\/2015\/437107","volume":"2015","author":"Li M.","year":"2015","unstructured":"Li M.; Reynolds C.M.; Segovia S.A.; Gray C.; Vickers M.H.; Developmental programming of nonalcoholic fatty liver disease: the effect of early life nutrition on susceptibility and disease severity in later life. BioMed Res Int 2015,2015,437107","journal-title":"BioMed Res Int"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.2337\/db14-0276","volume":"63","author":"Thorn S.R.","year":"2014","unstructured":"Thorn S.R.; Baquero K.C.; Newsom S.A.; Early life exposure to maternal insulin resistance has persistent effects on hepatic NAFLD in juvenile nonhuman primates. Diabetes 2014,63(8),2702-2713","journal-title":"Diabetes"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"E803","DOI":"10.1210\/jc.2010-2902","volume":"96","author":"Bush N.C.","year":"2011","unstructured":"Bush N.C.; Chandler-Laney P.C.; Rouse D.J.; Granger W.M.; Oster R.A.; Gower B.A.; Higher maternal gestational glucose concentration is associated with lower offspring insulin sensitivity and altered beta-cell function. J Clin Endocrinol Metab 2011,96(5),E803-E809","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1007\/s00125-015-3589-5","volume":"58","author":"Vlachov\u00e1 Z.","year":"2015","unstructured":"Vlachov\u00e1 Z.; Bytoft B.; Knorr S.; Increased metabolic risk in adolescent offspring of mothers with type 1 diabetes: the EPICOM study. Diabetologia 2015,58(7),1454-1463","journal-title":"Diabetologia"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/MPG.0000000000000520","volume":"60","author":"Patel K.R.","year":"2015","unstructured":"Patel K.R.; White F.V.; Deutsch G.H.; Hepatic steatosis is prevalent in stillborns delivered to women with diabetes mellitus. J Pediatr Gastroenterol Nutr 2015,60(2),152-158","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jhep.2016.05.020","volume":"65","author":"Suomela E.","year":"2016","unstructured":"Suomela E.; Oikonen M.; Pitk\u00e4nen N.; Childhood predictors of adult fatty liver. The cardiovascular risk in young finns study. J Hepatol 2016,65(4),784-790","journal-title":"J Hepatol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3109\/07853890.2013.801275","volume":"45","author":"Sandboge S.","year":"2013","unstructured":"Sandboge S.; Per\u00e4l\u00e4 M.M.; Salonen M.K.; Early growth and non-alcoholic fatty liver disease in adulthood\u2014the NAFLD liver fat score and equation applied on the Helsinki Birth Cohort Study. Ann Med 2013,45(5-6),430-437","journal-title":"Ann Med"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.2337\/dc07-0281","volume":"30","author":"Nobili V.","year":"2007","unstructured":"Nobili V.; Marcellini M.; Marchesini G.; Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. Diabetes Care 2007,30(10),2638-2640","journal-title":"Diabetes Care"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/ajg.2017.140","volume":"112","author":"Bugianesi E.","year":"2017","unstructured":"Bugianesi E.; Bizzarri C.; Rosso C.; Low birthweight increases the likelihood of severe steatosis in pediatric non-alcoholic fatty liver disease. Am J Gastroenterol 2017,112(8),1277-1286","journal-title":"Am J Gastroenterol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1172\/JCI32661","volume":"119","author":"McCurdy C.E.","year":"2009","unstructured":"McCurdy C.E.; Bishop J.M.; Williams S.M.; Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates. J Clin Invest 2009,119(2),323-335","journal-title":"J Clin Invest"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jhep.2011.10.018","volume":"56","author":"Li J.","year":"2012","unstructured":"Li J.; Huang J.; Li J.S.; Chen H.; Huang K.; Zheng L.; Accumulation of endoplasmic reticulum stress and lipogenesis in the liver through generational effects of high fat diets. J Hepatol 2012,56(4),900-907","journal-title":"J Hepatol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jnutbio.2011.03.008","volume":"23","author":"Takasaki M.","year":"2012","unstructured":"Takasaki M.; Honma T.; Yanaka M.; Continuous intake of a high-fat diet beyond one generation promotes lipid accumulation in liver and white adipose tissue of female mice. J Nutr Biochem 2012,23(6),640-645","journal-title":"J Nutr Biochem"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1210\/en.2012-1877","volume":"154","author":"Kruse M.","year":"2013","unstructured":"Kruse M.; Seki Y.; Vuguin P.M.; High-fat intake during pregnancy and lactation exacerbates high-fat diet-induced complications in male offspring in mice. Endocrinology 2013,154(10),3565-3576","journal-title":"Endocrinology"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12887-016-0585-y","volume":"16","author":"Patel S.","year":"2016","unstructured":"Patel S.; Lawlor D.A.; Callaway M.; Macdonald-Wallis C.; Sattar N.; Fraser A.; Association of maternal diabetes\/glycosuria and pre-pregnancy body mass index with offspring indicators of non-alcoholic fatty liver disease. BMC Pediatr 2016,16(1),47","journal-title":"BMC Pediatr"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jpeds.2017.09.008","volume":"192","author":"Bellatorre A.","year":"2018","unstructured":"Bellatorre A.; Scherzinger A.; Stamm E.; Martinez M.; Ringham B.; Dabelea D.; Fetal overnutrition and adolescent hepatic fat fraction: the exploring perinatal outcomes in children study. J Pediatr 2018,192,165-170.e1","journal-title":"J Pediatr"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrendo.2017.42","volume":"13","author":"Foulds C.E.","year":"2017","unstructured":"Foulds C.E.; Trevi\u00f1o L.S.; York B.; Walker C.L.; Endocrine-disrupting chemicals and fatty liver disease. Nat Rev Endocrinol 2017,13(8),445-457","journal-title":"Nat Rev Endocrinol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2174\/156652412798376161","volume":"12","author":"Polyzos S.A.","year":"2012","unstructured":"Polyzos S.A.; Kountouras J.; Deretzi G.; Zavos C.; Mantzoros C.S.; The emerging role of endocrine disruptors in pathogenesis of insulin resistance: A concept implicating nonalcoholic fatty liver disease. Curr Mol Med 2012,12(1),68-82","journal-title":"Curr Mol Med"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1210\/jc.2013-3199","volume":"99","author":"Breij L.M.","year":"2014","unstructured":"Breij L.M.; Kerkhof G.F.; Hokken-Koelega A.C.S.; Accelerated infant weight gain and risk for nonalcoholic fatty liver disease in early adulthood. J Clin Endocrinol Metab 2014,99(4),1189-1195","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jhep.2017.03.029","volume":"67","author":"Ayonrinde O.T.","year":"2017","unstructured":"Ayonrinde O.T.; Oddy W.H.; Adams L.A.; Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents. J Hepatol 2017,67(3),568-576","journal-title":"J Hepatol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1038\/s41467-018-06929-0","volume":"9","author":"Soderborg T.K.","year":"2018","unstructured":"Soderborg T.K.; Clark S.E.; Mulligan C.E.; The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD. Nat Commun 2018,9(1),4462","journal-title":"Nat Commun"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jnutbio.2015.08.024","volume":"29","author":"Dongiovanni P.","year":"2016","unstructured":"Dongiovanni P.; Lanti C.; Riso P.; Valenti L.; Nutritional therapy for nonalcoholic fatty liver disease. J Nutr Biochem 2016,29,1-11","journal-title":"J Nutr Biochem"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3961\/jpmph.2013.46.4.192","volume":"46","author":"Rani M.A.","year":"2013","unstructured":"Rani M.A.; Sathiyasekaran B.W.C.; Behavioural determinants for obesity: a cross-sectional study among urban adolescents in India. J Prev Med Public Health 2013,46(4),192-200","journal-title":"J Prev Med Public Health"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s42000-021-00339-6","volume":"21","author":"Vachliotis I.","year":"2022","unstructured":"Vachliotis I.; Goulas A.; Papaioannidou P.; Polyzos S.A.; Nonalcoholic fatty liver disease: lifestyle and quality of life. Hormones (Athens) 2022,21(1),41-49","journal-title":"Hormones (Athens)"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s11695-008-9549-0","volume":"20","author":"Kim C.H.","year":"2010","unstructured":"Kim C.H.; Kallman J.B.; Bai C.; Nutritional assessments of patients with non-alcoholic fatty liver disease. Obes Surg 2010,20(2),154-160","journal-title":"Obes Surg"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1016\/S2468-2667(18)30135-X","volume":"3","author":"Seidelmann S.B.","year":"2018","unstructured":"Seidelmann S.B.; Claggett B.; Cheng S.; Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Health 2018,3(9),e419-e428","journal-title":"Lancet Public Health"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1006\/pmed.1996.0082","volume":"25","author":"Neumark-Sztainer D.","year":"1996","unstructured":"Neumark-Sztainer D.; Story M.; Resnick M.D.; Blum R.W.; Correlates of inadequate fruit and vegetable consumption among adolescents. Prev Med 1996,25(5),497-505","journal-title":"Prev Med"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1001\/jama.282.16.1561","volume":"282","author":"Robinson T.N.","year":"1999","unstructured":"Robinson T.N.; Reducing children\u2019s television viewing to prevent obesity: A randomized controlled trial. JAMA 1999,282(16),1561-1567","journal-title":"JAMA"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"581461","DOI":"10.3389\/fped.2020.581461","volume":"8","author":"Kansra A.R.","year":"2021","unstructured":"Kansra A.R.; Lakkunarajah S.; Jay M.S.; Childhood and adolescent obesity: A review. Front Pediatr 2021,8,581461","journal-title":"Front Pediatr"},{"key":"ref=142","first-page":"3450","volume":"19","author":"Ozhan B.","year":"2015","unstructured":"Ozhan B.; Ersoy B.; Kiremitci S.; Ozkol M.; Taneli F.; Insulin sensitivity indices: fasting versus glucose-stimulated \u0131ndices in pediatric non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci 2015,19(18),3450-3458","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"e0140908","DOI":"10.1371\/journal.pone.0140908","volume":"10","author":"Anderson E.L.","year":"2015","unstructured":"Anderson E.L.; Howe L.D.; Jones H.E.; Higgins J.P.T.; Lawlor D.A.; Fraser A.; The prevalence of non-alcoholic fatty liver disease in children and adolescents: A systematic review and meta-analysis. PLoS One 2015,10(10),e0140908","journal-title":"PLoS One"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1471-2431-13-115","volume":"13","author":"Silveira L.S.","year":"2013","unstructured":"Silveira L.S.; Monteiro P.A.; Antunes B.M.M.; Intra-abdominal fat is related to metabolic syndrome and non-alcoholic fat liver disease in obese youth. BMC Pediatr 2013,13(1),115","journal-title":"BMC Pediatr"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2431-14-25","volume":"14","author":"Monteiro P.A.","year":"2014","unstructured":"Monteiro P.A.; de Moura Mello Antunes B.; Silveira L.S.; Christofaro D.G.D.; Fernandes R.A.; Freitas I.F.; Body composition variables as predictors of NAFLD by ultrasound in obese children and adolescents. BMC Pediatr 2014,14(1),25","journal-title":"BMC Pediatr"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1089\/met.2017.0001","volume":"15","author":"Ko Y.H.","year":"2017","unstructured":"Ko Y.H.; Wong T.C.; Hsu Y.Y.; Kuo K.L.; Yang S.H.; The correlation between body fat, visceral fat, and nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2017,15(6),304-311","journal-title":"Metab Syndr Relat Disord"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jhep.2007.02.007","volume":"47","author":"Lee J.Y.","year":"2007","unstructured":"Lee J.Y.; Kim K.M.; Lee S.G.; Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: A review of 589 consecutive liver biopsies in a single center. J Hepatol 2007,47(2),239-244","journal-title":"J Hepatol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1046\/j.1440-1746.2002.02846.x","volume":"17","author":"Omagari K.","year":"2002","unstructured":"Omagari K.; Kadokawa Y.; Masuda J.I.; Fatty liver in non-alcoholic non-overweight Japanese adults: Incidence and clinical characteristics. J Gastroenterol Hepatol 2002,17(10),1098-1105","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.metabol.2015.10.019","volume":"65","author":"Mathew H.","year":"2016","unstructured":"Mathew H.; Farr O.M.; Mantzoros C.S.; Metabolic health and weight: Understanding metabolically unhealthy normal weight or metabolically healthy obese patients. Metabolism 2016,65(1),73-80","journal-title":"Metabolism"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.2174\/1381612826666201125103047","volume":"27","year":"2021","unstructured":"Muzurovi\u0107 E, Stankovi\u0107 Z, Kova\u010devi\u0107 Z, \u0160krijelj B\u0160, Mikhailidis DP. Inflammatory markers associated with diabetes mellitus \u2013 old and new players. Curr Pharm Des 2021,27(27),3020-3035","journal-title":"Curr Pharm Des"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.metabol.2015.11.006","volume":"65","author":"Polyzos S.A.","year":"2016","unstructured":"Polyzos S.A.; Kountouras J.; Mantzoros C.S.; Adipokines in nonalcoholic fatty liver disease. Metabolism 2016,65(8),1062-1079","journal-title":"Metabolism"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1517\/13543784.15.8.917","volume":"15","author":"Barb D.","year":"2006","unstructured":"Barb D.; Pazaitou-Panayiotou K.; Mantzoros C.S.; Adiponectin: a link between obesity and cancer. Expert Opin Investig Drugs 2006,15(8),917-931","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2174\/156652409787847191","volume":"9","author":"Polyzos S.","year":"2009","unstructured":"Polyzos S.; Kountouras J.; Zavos C.; Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009,9(3),299-314","journal-title":"Curr Mol Med"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"e0260313","DOI":"10.1371\/journal.pone.0260313","volume":"16","author":"Goyale A.","year":"2021","unstructured":"Goyale A.; Jain A.; Smith C.; Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. PLoS One 2021,16(11),e0260313","journal-title":"PLoS One"},{"key":"ref=155","first-page":"407","volume":"14","author":"Shah J.","year":"2018","unstructured":"Shah J.; Okubote T.; Alkhouri N.; Overview of updated practice guidelines for pediatric nonalcoholic fatty liver disease. Gastroenterol Hepatol (N Y) 2018,14(7),407-414","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"154305","DOI":"10.1016\/j.metabol.2020.154305","volume":"109","year":"2020","unstructured":"Muzurovi\u0107 E, Mikhailidis DP, Mantzoros C. Commentary: From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based. Metabolism 2020,109,154305","journal-title":"Metabolism"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.3390\/nu12123860","volume":"12","author":"Parra-Vargas M.","year":"2020","unstructured":"Parra-Vargas M.; Rodriguez-Echevarria R.; Jimenez-Chillaron J.C.; Nutritional approaches for the management of nonalcoholic fatty liver disease: An evidence-based review. Nutrients 2020,12(12),3860","journal-title":"Nutrients"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"109199","DOI":"10.1016\/j.cbi.2020.109199","volume":"330","author":"Lian C.Y.","year":"2020","unstructured":"Lian C.Y.; Zhai Z.Z.; Li Z.F.; Wang L.; High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms. Chem Biol Interact 2020,330,109199","journal-title":"Chem Biol Interact"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3945\/ajcn.2010.30185","volume":"92","author":"Davis J.N.","year":"2010","unstructured":"Davis J.N.; L\u00ea K.A.; Walker R.W.; Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr 2010,92(6),1522-1527","journal-title":"Am J Clin Nutr"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jama.2018.20579","volume":"321","author":"Schwimmer J.B.","year":"2019","unstructured":"Schwimmer J.B.; Ugalde-Nicalo P.; Welsh J.A.; Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys. JAMA 2019,321(3),256-265","journal-title":"JAMA"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1089\/chi.2013.0022","volume":"9","author":"Ramon-Krauel M.","year":"2013","unstructured":"Ramon-Krauel M.; Salsberg S.L.; Ebbeling C.B.; A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes 2013,9(3),252-260","journal-title":"Child Obes"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.3748\/wjg.v24.i19.2083","volume":"24","author":"Anania C.","year":"2018","unstructured":"Anania C.; Perla F.M.; Olivero F.; Pacifico L.; Chiesa C.; Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol 2018,24(19),2083-2094","journal-title":"World J Gastroenterol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/MCO.0000000000000476","volume":"21","author":"Sekkarie A.","year":"2018","unstructured":"Sekkarie A.; Welsh J.A.; Vos M.B.; Carbohydrates and diet patterns in nonalcoholic fatty liver disease in children and adolescents. Curr Opin Clin Nutr Metab Care 2018,21(4),283-288","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jhep.2016.12.025","volume":"66","author":"Mosca A.","year":"2017","unstructured":"Mosca A.; Nobili V.; De Vito R.; Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. J Hepatol 2017,66(5),1031-1036","journal-title":"J Hepatol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"e12759","DOI":"10.1111\/ijpo.12759","volume":"16","author":"DiStefano J.K.","year":"2021","unstructured":"DiStefano J.K.; Shaibi G.Q.; The relationship between excessive dietary fructose consumption and paediatric fatty liver disease. Pediatr Obes 2021,16(6),e12759","journal-title":"Pediatr Obes"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/liv.13661","volume":"38","author":"Nobili V.","year":"2018","unstructured":"Nobili V.; Mosca A.; De Vito R.; Raponi M.; Scorletti E.; Byrne C.D.; Liver zonation in children with non-alcoholic fatty liver disease: Associations with dietary fructose and uric acid concentrations. Liver Int 2018,38(6),1102-1109","journal-title":"Liver Int"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1053\/j.gastro.2017.05.043","volume":"153","author":"Schwarz J.M.","year":"2017","unstructured":"Schwarz J.M.; Noworolski S.M.; Erkin-Cakmak A.; Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology 2017,153(3),743-752","journal-title":"Gastroenterology"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1542\/peds.2009-2037","volume":"125","author":"Barton M.","year":"2010","unstructured":"Barton M.; Barton M.; Screening for obesity in children and adolescents: US Preventive Services Task Force recommendation statement. Pediatrics 2010,125(2),361-367","journal-title":"Pediatrics"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/adc.2008.143594","volume":"94","author":"Reinehr T.","year":"2009","unstructured":"Reinehr T.; Schmidt C.; Toschke A.M.; Andler W.; Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. Arch Dis Child 2009,94(6),437-442","journal-title":"Arch Dis Child"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MPG.0b013e31822cdedf","volume":"54","author":"Gr\u00f8nb\u00e6k H.","year":"2012","unstructured":"Gr\u00f8nb\u00e6k H.; Lange A.; Birkeb\u00e6k N.H.; Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J Pediatr Gastroenterol Nutr 2012,54(2),223-228","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MEG.0b013e32835793ac","volume":"24","author":"de Piano A.","year":"2012","unstructured":"de Piano A.; de Mello M.T.; Sanches P.L.; Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents. Eur J Gastroenterol Hepatol 2012,24(11),1","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1249\/MSS.0b013e3181df16d9","volume":"42","author":"Van Der Heijden G.J.","year":"2010","unstructured":"Van Der Heijden G.J.; Wang Z.J.; Chu Z.; Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth. Med Sci Sports Exerc 2010,42(11),1973-1980","journal-title":"Med Sci Sports Exerc"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.2337\/db12-0214","volume":"61","author":"Lee S.","year":"2012","unstructured":"Lee S.; Bacha F.; Hannon T.; Kuk J.L.; Boesch C.; Arslanian S.; Effects of aerobic versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in obese adolescent boys: A randomized, controlled trial. Diabetes 2012,61(11),2787-2795","journal-title":"Diabetes"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"E1222","DOI":"10.1152\/ajpendo.00285.2013","volume":"305","author":"Lee S.","year":"2013","unstructured":"Lee S.; Deldin A.R.; White D.; Aerobic exercise but not resistance exercise reduces intrahepatic lipid content and visceral fat and improves insulin sensitivity in obese adolescent girls: A randomized controlled trial. Am J Physiol Endocrinol Metab 2013,305(10),E1222-E1229","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1089\/chi.2017.0027","volume":"13","author":"Gonz\u00e1lez-Ruiz K.","year":"2017","unstructured":"Gonz\u00e1lez-Ruiz K.; Ram\u00edrez-V\u00e9lez R.; Correa-Bautista J.E.; Peterson M.D.; Garc\u00eda-Hermoso A.; The effects of exercise on abdominal fat and liver enzymes in pediatric obesity: A systematic review and meta-analysis. Child Obes 2017,13(4),272-282","journal-title":"Child Obes"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"Polyzos S.A.","year":"2019","unstructured":"Polyzos S.A.; Kountouras J.; Mantzoros C.S.; Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019,92,82-97","journal-title":"Metabolism"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/hep.22336","volume":"48","author":"Nobili V.","year":"2008","unstructured":"Nobili V.; Manco M.; Devito R.; Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial. Hepatology 2008,48(1),119-128","journal-title":"Hepatology"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/MPG.0b013e3181d70468","volume":"51","author":"Pozzato C.","year":"2010","unstructured":"Pozzato C.; Verduci E.; Scaglioni S.; Liver fat change in obese children after a 1-year nutrition-behavior intervention. J Pediatr Gastroenterol Nutr 2010,51(3),331-335","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1136\/adc.2010.199760","volume":"96","author":"Koot B.G.P.","year":"2011","unstructured":"Koot B.G.P.; van der Baan-Slootweg O.H.; Tamminga-Smeulders C.L.J.; Lifestyle intervention for non-alcoholic fatty liver disease: Prospective cohort study of its efficacy and factors related to improvement. Arch Dis Child 2011,96(7),669-674","journal-title":"Arch Dis Child"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3748\/wjg.14.1598","volume":"14","author":"Wang C.L.","year":"2008","unstructured":"Wang C.L.; Liang L.; Fu J.F.; Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol 2008,14(10),1598-1602","journal-title":"World J Gastroenterol"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"345","DOI":"10.5604\/01.3001.0011.7380","volume":"17","author":"Utz-Melere M.","year":"2018","unstructured":"Utz-Melere M.; Targa-Ferreira C.; Lessa-Horta B.; Epifanio M.; Mouzaki M.; Mattos A.A.; Non-alcoholic fatty liver disease in children and adolescents: Lifestyle change - a systematic review and meta-analysis. Ann Hepatol 2018,17(3),345-354","journal-title":"Ann Hepatol"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5114\/ceh.2019.83152","volume":"5","author":"Flisiak-Jackiewicz M.","year":"2019","unstructured":"Flisiak-Jackiewicz M.; Lebensztejn D.M.; Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children. Clin Exp Hepatol 2019,5(1),11-21","journal-title":"Clin Exp Hepatol"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"e0181095","DOI":"10.1371\/journal.pone.0181095","volume":"12","author":"Mameli C.","year":"2017","unstructured":"Mameli C.; Krakauer J.C.; Krakauer N.Y.; Effects of a multidisciplinary weight loss intervention in overweight and obese children and adolescents: 11 years of experience. PLoS One 2017,12(7),e0181095","journal-title":"PLoS One"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1089\/chi.2015.0126","volume":"12","author":"Sayin F.K.","year":"2016","unstructured":"Sayin F.K.; Buyukinan M.; Sleep duration and media time have a major impact on insulin resistance and metabolic risk factors in obese children and adolescents. Child Obes 2016,12(4),272-278","journal-title":"Child Obes"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/MED.0000000000000125","volume":"22","author":"Miller A.L.","year":"2015","unstructured":"Miller A.L.; Lumeng J.C.; LeBourgeois M.K.; Sleep patterns and obesity in childhood. Curr Opin Endocrinol Diabetes Obes 2015,22(1),41-47","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1080\/14656566.2016.1225727","volume":"17","author":"Mintziori G.","year":"2016","unstructured":"Mintziori G.; Polyzos S.A.; Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opin Pharmacother 2016,17(14),1937-1946","journal-title":"Expert Opin Pharmacother"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hep.29897","volume":"68","author":"Polyzos S.A.","year":"2018","unstructured":"Polyzos S.A.; Kountouras J.; Anastasiadis S.; Doulberis M.; Katsinelos P.; Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach? Hepatology 2018,68(1),389","journal-title":"Hepatology"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cts.12839","volume":"14","author":"Attia S.L.","year":"2021","unstructured":"Attia S.L.; Softic S.; Mouzaki M.; Evolving role for pharmacotherapy in NAFLD\/NASH. Clin Transl Sci 2021,14(1),11-19","journal-title":"Clin Transl Sci"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.metabol.2018.10.010","volume":"92","author":"Pilitsi E.","year":"2019","unstructured":"Pilitsi E.; Farr O.M.; Polyzos S.A.; Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism 2019,92,170-192","journal-title":"Metabolism"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/j.1365-2036.2005.02420.x","volume":"21","author":"Schwimmer J.B.","year":"2005","unstructured":"Schwimmer J.B.; Middleton M.S.; Deutsch R.; Lavine J.E.; A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005,21(7),871-879","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1001\/jama.2011.520","volume":"305","author":"Lavine J.E.","year":"2011","unstructured":"Lavine J.E.; Schwimmer J.B.; Van Natta M.L.; Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 2011,305(16),1659-1668","journal-title":"JAMA"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"1756284820974917","DOI":"10.1177\/1756284820974917","volume":"13","author":"Abdel-Maboud M.","year":"2020","unstructured":"Abdel-Maboud M.; Menshawy A.; Menshawy E.; Emara A.; Alshandidy M.; Eid M.; The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: A systematic review, meta-analysis, and meta-regression. Therap Adv Gastroenterol 2020,13,1756284820974917","journal-title":"Therap Adv Gastroenterol"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"101530","DOI":"10.1016\/j.clinre.2020.08.008","volume":"45","author":"Lin M.","year":"2021","unstructured":"Lin M.; Zeng H.; Deng G.; Lei J.; Li J.; Vitamin E in paediatric non-alcoholic fatty liver disease: A meta-analysis. Clin Res Hepatol Gastroenterol 2021,45(3),101530","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1111\/jgh.12541","volume":"29","author":"Black L.J.","year":"2014","unstructured":"Black L.J.; Jacoby P.; She Ping-Delfos W.C.; Low serum 25-hydroxyvitamin D concentrations associate with non-alcoholic fatty liver disease in adolescents independent of adiposity. J Gastroenterol Hepatol 2014,29(6),1215-1222","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/MPG.0000000000000598","volume":"60","author":"Hourigan S.K.","year":"2015","unstructured":"Hourigan S.K.; Abrams S.; Yates K.; Relation between vitamin D status and nonalcoholic fatty liver disease in children. J Pediatr Gastroenterol Nutr 2015,60(3),396-404","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1530\/EJE-13-0609","volume":"170","author":"Nobili V.","year":"2014","unstructured":"Nobili V.; Giorgio V.; Liccardo D.; Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. Eur J Endocrinol 2014,170(4),547-553","journal-title":"Eur J Endocrinol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00431-021-04243-4","volume":"181","author":"El Amrousy D.","year":"2022","unstructured":"El Amrousy D.; Abdelhai D.; Shawky D.; Vitamin D and nonalcoholic fatty liver disease in children: A randomized controlled clinical trial. Eur J Pediatr 2022,181(2),579-586","journal-title":"Eur J Pediatr"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jpeds.2018.02.038","volume":"198","author":"Harlow K.E.","year":"2018","unstructured":"Harlow K.E.; Africa J.A.; Wells A.; Clinically actionable hypercholesterolemia and hypertriglyceridemia in children with nonalcoholic fatty liver disease. J Pediatr 2018,198,76-83.e2","journal-title":"J Pediatr"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","volume":"71","author":"Athyros V.G.","year":"2017","unstructured":"Athyros V.G.; Alexandrides T.K.; Bilianou H.; The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metabolism 2017,71,17-32","journal-title":"Metabolism"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/adc.2010.192401","volume":"96","author":"Nobili V.","year":"2011","unstructured":"Nobili V.; Bedogni G.; Alisi A.; Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: Double-blind randomised controlled clinical trial. Arch Dis Child 2011,96(4),350-353","journal-title":"Arch Dis Child"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1089\/jmf.2013.0043","volume":"16","author":"Nobili V.","year":"2013","unstructured":"Nobili V.; Bedogni G.; Donati B.; Alisi A.; Valenti L.; The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. J Med Food 2013,16(10),957-960","journal-title":"J Med Food"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1139\/apnm-2016-0689","volume":"42","author":"Z\u00f6hrer E.","year":"2017","unstructured":"Z\u00f6hrer E.; Alisi A.; Jahnel J.; Efficacy of docosahexaenoic acid\u2013choline\u2013vitamin E in paediatric NASH: A randomized controlled clinical trial. Appl Physiol Nutr Metab 2017,42(9),948-954","journal-title":"Appl Physiol Nutr Metab"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"e0168216","DOI":"10.1371\/journal.pone.0168216","volume":"11","author":"Della Corte C.","year":"2016","unstructured":"Della Corte C.; Carpino G.; De Vito R.; Docosahexanoic acid plus vitamin D treatment improves features of NAFLD in children with serum vitamin D deficiency: Results from a single centre trial. PLoS One 2016,11(12),e0168216","journal-title":"PLoS One"},{"key":"ref=204","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jpeds.2015.01.056","volume":"166","author":"Janczyk W","year":"2015","unstructured":"Janczyk W; Lebensztejn D; , Wierzbicka-Ruci\u0144ska A, et al. Omega-3 fatty acids therapy in children with nonalcoholic fatty liver disease: A randomized controlled trial. J Pediatr 2015,166,1358-1363","journal-title":"J Pediatr"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/MCG.0000000000000099","volume":"49","author":"Dasarathy S.","year":"2015","unstructured":"Dasarathy S.; Dasarathy J.; Khiyami A.; Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2015,49(2),137-144","journal-title":"J Clin Gastroenterol"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00018-019-03011-w","volume":"76","author":"Safari Z.","year":"2019","unstructured":"Safari Z.; G\u00e9rard P.; The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 2019,76(8),1541-1558","journal-title":"Cell Mol Life Sci"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5005\/jp-journals-10018-1233","volume":"7","author":"Lavekar A.S.","year":"2017","unstructured":"Lavekar A.S.; Raje D.V.; Lavekar A.A.A.; Lavekar A.; Role of probiotics in the treatment of nonalcoholic fatty liver disease: A meta-analysis. Euroasian J Hepatogastroenterol 2017,7(2),130-137","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/MPG.0b013e31821f9b85","volume":"52","author":"Vajro P.","year":"2011","unstructured":"Vajro P.; Mandato C.; Licenziati M.R.; Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011,52(6),740-743","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"154203","DOI":"10.1016\/j.metabol.2020.154203","volume":"111","author":"Polyzos S.A.","year":"2020","unstructured":"Polyzos S.A.; Kang E.S.; Boutari C.; Rhee E.J.; Mantzoros C.S.; Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020,111,154203","journal-title":"Metabolism"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s13679-020-00409-7","volume":"9","author":"Page L.C.","year":"2020","unstructured":"Page L.C.; Freemark M.; Role of GLP-1 receptor agonists in pediatric obesity: Benefits, risks, and approaches to patient selection. Curr Obes Rep 2020,9(4),391-401","journal-title":"Curr Obes Rep"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S2213-8587(17)30109-2","volume":"5","author":"Katsiki N.","year":"2017","unstructured":"Katsiki N.; Athyros V.G.; Karagiannis A.; Mikhailidis D.P.; Semaglutide, lipid-lowering drugs, and NAFLD. Lancet Diabetes Endocrinol 2017,5(5),329-330","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcard.2022.07.017","volume":"365","author":"Janez A.","year":"2022","unstructured":"Janez A.; Muzurovic E.; Stoian A.P.; Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group. Int J Cardiol 2022,365,8-18","journal-title":"Int J Cardiol"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1080\/14656566.2020.1795132","volume":"21","year":"2020","unstructured":"Muzurovi\u0107 E, Mikhailidis DP. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. Expert Opin Pharmacother 2020,21(17),2125-2135","journal-title":"Expert Opin Pharmacother"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"107619","DOI":"10.1016\/j.jdiacomp.2020.107619","volume":"34","year":"2020","unstructured":"Muzurovi\u0107 E, Dragni\u0107 S, Medenica S, Smolovi\u0107 B, Bulaji\u0107 P, Mikhailidis DP. Weight-centric pharmacological management of type 2 diabetes mellitus \u2013 An essential component of cardiovascular disease prevention. J Diabetes Complications 2020,34(8),107619","journal-title":"J Diabetes Complications"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1053\/j.gastro.2016.08.027","volume":"151","author":"Schwimmer J.B.","year":"2016","unstructured":"Schwimmer J.B.; Lavine J.E.; Wilson L.A.; In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores. Gastroenterology 2016,151(6),1141-1154.e9","journal-title":"Gastroenterology"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/gutjnl-2016-312431","volume":"66","author":"Rotman Y.","year":"2017","unstructured":"Rotman Y.; Sanyal A.J.; Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut 2017,66(1),180-190","journal-title":"Gut"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.metabol.2016.05.013","volume":"65","author":"Polyzos S.A.","year":"2016","unstructured":"Polyzos S.A.; Mantzoros C.S.; Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. Metabolism 2016,65(9),1297-1306","journal-title":"Metabolism"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/MPG.0000000000000715","volume":"60","author":"Nobili V.","year":"2015","unstructured":"Nobili V.; Vajro P.; Dezsofi A.; Indications and limitations of bariatric intervention in severely obese children and adolescents with and without nonalcoholic steatohepatitis: ESPGHAN hepatology committee position statement. J Pediatr Gastroenterol Nutr 2015,60(4),550-561","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"4697194","DOI":"10.1155\/2017\/4697194","volume":"2017","author":"Nguyen V.","year":"2017","unstructured":"Nguyen V.; Li J.; Gan J.; Outcomes following serial intragastric balloon therapy for obesity and nonalcoholic fatty liver disease in a single centre. Can J Gastroenterol Hepatol 2017,2017,4697194","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.21037\/atm.2019.09.67","volume":"8","author":"Claudia Gollisch K.S.","year":"2020","unstructured":"Claudia Gollisch K.S.; Raddatz D.; Endoscopic intragastric balloon: A gimmick or a viable option for obesity? Ann Transl Med 2020,8(Suppl. 1),S8","journal-title":"Ann Transl Med"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"150888","DOI":"10.1016\/j.sempedsurg.2020.150888","volume":"29","author":"Lamoshi A.","year":"2020","unstructured":"Lamoshi A.; Chernoguz A.; Harmon C.M.; Helmrath M.; Complications of bariatric surgery in adolescents. Semin Pediatr Surg 2020,29(1),150888","journal-title":"Semin Pediatr Surg"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jpeds.2016.08.101","volume":"180","author":"Manco M.","year":"2017","unstructured":"Manco M.; Mosca A.; De Peppo F.; The benefit of sleeve gastrectomy in obese adolescents on nonalcoholic steatohepatitis and hepatic fibrosis. J Pediatr 2017,180,31-37.e2","journal-title":"J Pediatr"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jpeds.2017.10.036","volume":"194","author":"Nobili V.","year":"2018","unstructured":"Nobili V.; Carpino G.; De Peppo F.; Laparoscopic sleeve gastrectomy improves nonalcoholic fatty liver disease\u2013related liver damage in adolescents by reshaping cellular interactions and hepatic adipocytokine production. J Pediatr 2018,194,100-108.e3","journal-title":"J Pediatr"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jpeds.2019.07.037","volume":"216","author":"Franchitto A.","year":"2020","unstructured":"Franchitto A.; Carpino G.; Alisi A.; The contribution of the adipose tissue-liver axis in pediatric patients with nonalcoholic fatty liver disease after laparoscopic sleeve gastrectomy. J Pediatr 2020,216,117-127.e2","journal-title":"J Pediatr"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.soard.2011.09.009","volume":"8","author":"Michalsky M.","year":"2012","unstructured":"Michalsky M.; Reichard K.; Inge T.; Pratt J.; Lenders C.; ASMBS pediatric committee best practice guidelines. Surg Obes Relat Dis 2012,8(1),1-7","journal-title":"Surg Obes Relat Dis"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.soard.2018.03.019","volume":"14","author":"Pratt J.S.A.","year":"2018","unstructured":"Pratt J.S.A.; Browne A.; Browne N.T.; ASMBS pediatric metabolic and bariatric surgery guidelines, 2018. Surg Obes Relat Dis 2018,14(7),882-901","journal-title":"Surg Obes Relat Dis"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3748\/wjg.v24.i14.1491","volume":"24","author":"Mikolasevic I.","year":"2018","unstructured":"Mikolasevic I.; Filipec-Kanizaj T.; Mijic M.; Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? World J Gastroenterol 2018,24(14),1491-1506","journal-title":"World J Gastroenterol"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"Wong R.J.","year":"2015","unstructured":"Wong R.J.; Aguilar M.; Cheung R.; Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015,148(3),547-555","journal-title":"Gastroenterology"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/TP.0000000000002490","volume":"103","author":"Cananzi M.","year":"2019","unstructured":"Cananzi M.; Vajro P.; Rela M.; Dhawan A.; NAFLD and liver transplantation in children\u2014working group report from the ILTS single topic conference on NAFLD. Transplantation 2019,103(1),68-70","journal-title":"Transplantation"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1097\/TP.0000000000002916","volume":"103","author":"Saeed N.","year":"2019","unstructured":"Saeed N.; Glass L.; Sharma P.; Shannon C.; Sonnenday C.J.; Tincopa M.A.; Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant: Systematic review and meta-analysis. Transplantation 2019,103(11),e345-e354","journal-title":"Transplantation"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.3748\/wjg.v23.i36.6549","volume":"23","author":"Singh S.","year":"2017","unstructured":"Singh S.; Osna N.A.; Kharbanda K.K.; Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol 2017,23(36),6549-6570","journal-title":"World J Gastroenterol"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.metabol.2016.01.008","volume":"65","author":"Crespo M.","year":"2016","unstructured":"Crespo M.; Lappe S.; Feldstein A.E.; Alkhouri N.; Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Metabolism 2016,65(8),1161-1171","journal-title":"Metabolism"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","volume":"137","author":"Kotronen A.","year":"2009","unstructured":"Kotronen A.; Peltonen M.; Hakkarainen A.; Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009,137(3),865-872","journal-title":"Gastroenterology"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/MPG.0b013e31822960be","volume":"53","author":"Maffeis C.","year":"2011","unstructured":"Maffeis C.; Banzato C.; Rigotti F.; Biochemical parameters and anthropometry predict NAFLD in obese children. J Pediatr Gastroenterol Nutr 2011,53(6),590-593","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cct.2017.07.015","volume":"61","author":"Barritt A.S.","year":"2017","unstructured":"Barritt A.S.; Gitlin N.; Klein S.; Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. Contemp Clin Trials 2017,61,33-38","journal-title":"Contemp Clin Trials"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cct.2018.11.003","volume":"75","author":"Mann J.P.","year":"2018","unstructured":"Mann J.P.; Vreugdenhil A.; Socha P.; European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. Contemp Clin Trials 2018,75,67-71","journal-title":"Contemp Clin Trials"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570161121666221118155136","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211053\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570161121666221118155136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T10:41:17Z","timestamp":1692182477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211053\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":236,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161121666221118155136","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-03-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}